cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
I Mab
6 own
2 watching
Current Price
$6.8
$0.39
(6.08%)
logo-imab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
56.87M
52-Week High
52-Week High
29.6
52-Week Low
52-Week Low
3.19
Average Volume
Average Volume
0.39M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
20.367
iconMarket Capitalization56.87M
icon52-Week High29.6
icon52-Week Low3.19
iconAverage Volume0.39M
iconDividend Yield--
iconP/E Ratio20.367
What does the I Mab do?
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People s Republic of China.
Read More
News & Events about I Mab.
PR Newswire
29days ago
Thinking about buying stock in Dermata Therapeutics, Silo Pharma, IQIYI, First Wave BioPharma, or I-Mab? Thinking about buying stock in Dermata Therapeutics, Silo Pharma, IQIYI, First Wave BioPharma, or I-Mab? PR Newswire NEW YORK, Dec. 30, 2022 NEW YORK, Dec. 30, 2022 /PRNewswire...
TheStreet.com - Investing
1month ago
Here are the most undervalued stocks tracked by Morningstar, as measured by its fair-value estimates.Here are the most undervalued stocks tracked by Morningstar, as measured by its fair-value estimates.With the S&P 500 having dropped 19% year to date, you might be thinking now is the time to pick up...
PR Newswire
3 months ago
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 PR Newswire GAITHERSBURG, MD. and SHANGHAI, China, Oct. 5, 2022 GAITHERSBURG...
PR Newswire
4 months ago
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic...
Business Wire
4 months ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab (I-Mab or the Company) (NASDAQ: IMAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading...
Frequently Asked Questions
Frequently Asked Questions
What is I Mab share price today?
plus_minus_icon
Can Indians buy I Mab shares?
plus_minus_icon
How can I buy I Mab shares from India?
plus_minus_icon
Can Fractional shares of I Mab be purchased?
plus_minus_icon
What are the documents required to start investing in I Mab stocks?
plus_minus_icon
What is today’s traded volume of I Mab?
plus_minus_icon
What is today’s market capitalisation of I Mab?
plus_minus_icon
What is the 52-Week High and Low Range of I Mab?
plus_minus_icon
What percentage is I Mab down from its 52-Week High?
plus_minus_icon
What percentage is I Mab up from its 52-Week Low?
plus_minus_icon
Current Price
$6.8
$0.39
(6.08%)
logo-imab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00